Evidence map›Paper›PMID 41278274›Full record

ArticleFrontiers in oncology2025

Papillary thyroid carcinoma measuring 1.0 cm or less: an epidemiological and clinicopathological study.

Imad A El Hag, Raghad Tallab

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Imad A El HagDepartment of Pathology and Laboratory medicine, Security Forces Hospital, Riyadh, Saudi Arabia.
Raghad TallabDepartment of Pathology and Laboratory medicine, Security Forces Hospital, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence of papillary thyroid microcarcinoma (PTMC) measuring 1 cm or less has noticeably increased over the past 30 years, particularly among clinically significant subgroups that are diagnosed chiefly preoperatively. Methods: This retrospective study investigated the rate of occurrence and the pathological high-risk features of PTMC discovered incidentally during thyroidectomies for benign thyroid diseases, as well as those diagnosed preoperatively (non-incidental), in a sample of 1,408 thyroidectomies. Results: PTMC accounted for 30.5% of all resected malignant thyroid tumors, with 53% being incidental and 47% non-incidental. The incidence of incidental PTMC has increased twofold over the past seven years, from 4.5% to 9.0%, while the incidence of the non-incidental subgroup has increased tenfold, from 0.9% to 9.0%. Compared to incidental cases, non-incidental cases were more likely to affect males, exhibited significantly larger tumors (7.2 mm versus 3.7 mm), and had higher rates of multiplicity (49.4% vs. 23.6%) and bilaterality (36.7% vs. 16.7%). Non-incidental cases also had higher rates of lymph node metastasis (25.9% vs. 4.2%) and greater margin involvement (34.4% vs. 16.7%). Extrathyroidal extension occurred exclusively in approximately 2.5% of the non-incidental cases. The most aggressive PTMC subtype is the tall cell subtype (TCS), followed by the classic subtype, which is observed in 30% and 29% of non-incidental cases, respectively. Follicular subtypes exhibit indolent behavior, as observed in 11% of non-incidental cases. An account of the TCS morphology is also provided. Conclusion: The incidence of PTMC has dramatically increased in the non-screened population. Male sex, tumor size >5 mm, and TCS subtype are risk factors for aggressive behavior.

Indexed as

high-riskincidentalnon-incidentalPTMCsubtypes

Identifiers

PMID41278274
PMCPMC12631284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.